Abstract
The new era of patient-centric spatiotemporal genomic trials has just begun. Moreover, the combination of Next-generation sequencing (NGS) including ChiP-seq and Hi-C technologies enable deeper exploration of aberrant regulatory networks. Single. These two emerging research directions could realize a medium term and long-term horizon for evidence –based development of biomarkers and targeted drugs as well as pharmaceutical controllability of perturbated circuits respectively.
(Citation: Gastric & Breast Cancer 2019; 14(1): 118-123)
|
